<DOC>
	<DOCNO>NCT01892722</DOCNO>
	<brief_summary>To evaluate safety efficacy fingolimod vs. interferon beta-1a i.m . pedaitric patient multiple sclerosis</brief_summary>
	<brief_title>Safety Efficacy Fingolimod Pediatric Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>diagnosis multiple sclerosis least one MS relapse previous year two MS relapse previous 2 year evidence Gd enhance lesion MRI within 6 month EDSS score 0 5.5 , inclusive patient progressive MS patient active , chronic disease immune system MS patient meet definition ADEM patient severe cardiac disease significant finding screen ECG . patient severe renal insufficiency Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pediatric</keyword>
	<keyword>multiple sclerosis</keyword>
</DOC>